Logo of Pro Medicus (ASX:PME)Latest Pro Medicus (ASX:PME) News

Page 2
Page 2 of 5

Healthcare Wrap - Week 23 (1 June -> 5 June) 2026

Healthcare stocks split into two camps this week. Buyers chased clear commercial wins, while several halted names gave back early excitement once trading resumed. The biggest moves came from a collapse in Opthea, a surge in Control Bionics, and a strong jump in Biome Australia after a margin-boosting manufacturing deal.
Logan Eniac
6 June 2026

Pro Medicus Secures A$16M Five-Year Renewal with Ohio State Medical Center

Pro Medicus' U.S. subsidiary Visage Imaging has extended its contract with The Ohio State University Wexner Medical Center for five years, adding new Visage 7 modules and increasing transaction fees, underpinning strong client retention and platform demand.
Ada Torres
4 June 2026

Pro Medicus Expands US Footprint with $16M TidalHealth Cloud Imaging Deal

Pro Medicus secures a $16 million, 7-year cloud imaging contract with TidalHealth, complementing recent major wins and contract renewals that underscore its growing dominance in North American healthcare IT.
Ada Torres
1 June 2026

Healthcare Wrap - Week 21 (18 May -> 22 May) 2026

Imugene, Vitasora and Adherium led a volatile week in healthcare shares, as trial news and software rollouts battled capital raisings, legal issues and weak sentiment in smaller biotech names. Big contracts, takeover steps and record earnings kept the sector busy, but several stocks still fell even after reporting clear operational progress.
Logan Eniac
23 May 2026

Pro Medicus Secures A$90M 7-Year Cloud Imaging Deal with Beth Israel Lahey Health

Pro Medicus’ US arm Visage Imaging has landed a significant 7-year, A$90 million contract to deploy its cloud-based Visage 7 platform across Beth Israel Lahey Health, marking another major foothold in North America's healthcare imaging market.
Ada Torres
18 May 2026

Healthcare Wrap - Week 16 (13 Apr -> 17 Apr) 2026

Big gains came from contracts, approvals and takeover interest, while several capital raisings and debt deals drew a cooler response. Diagnostics, radiopharma and medtech led the week, with buyers rewarding companies that showed clear sales, supply or hospital access.
Logan Eniac
18 Apr 2026

Pro Medicus Extends Northwestern Medicine Contract to A$37M with Increased Fees

Pro Medicus has secured a 5-year, A$37 million contract renewal with Northwestern Medicine, featuring higher minimum usage commitments and increased fees per transaction, reflecting growth in exam volumes.
Ada Torres
13 Apr 2026

Market Wrap - Week 15 (6 Apr -> 10 Apr) 2026

Rare earths, lithium and antimony stocks drove the week, while a handful of capital raisings and profit warnings hit hard. The biggest gains came from drilling wins and deal news. The sharpest falls came where investors faced dilution, weaker earnings or takeover friction.
Logan Eniac
11 Apr 2026

Healthcare Wrap - Week 15 (6 Apr -> 10 Apr) 2026

Small-cap healthcare names produced the biggest share-price swings this week, while larger names advanced on sales growth, trial progress and fresh contracts. Investors rewarded companies that showed clear commercial traction, but fundraising and weak follow-through punished others.
Logan Eniac
11 Apr 2026

Pro Medicus Secures A$23M 5-Year Cloud Imaging Deal with University of Maryland Medical System

Pro Medicus Limited’s U.S. subsidiary has signed a five-year, A$23 million contract to implement its cloud-based Visage 7 Enterprise Imaging Platform across the University of Maryland Medical System. The rollout is planned to begin immediately, with go-live targeted for early 2027.
Ada Torres
8 Apr 2026

Healthcare Wrap - Week 14 (30 Mar -> 3 Apr) 2026

Big moves came from point-of-care testing and a sharp sell-off in two names despite upbeat news. Meanwhile, several smaller caps pushed trials and regulatory files forward, giving investors clear dates to watch.
Logan Eniac
4 Apr 2026

Pro Medicus Initiates On-Market Buy-Back of Up to 10% of Shares

Pro Medicus Limited has announced an on-market buy-back program targeting up to 10% of its ordinary shares, aiming to return capital to shareholders without requiring approval.
Ada Torres
1 Apr 2026